Nebius: 2 Reasons Why You Should Buy The Bloodbath
Nebius (NBIS) reported strong Q3 results with 571% Y/Y revenue growth, positive adjusted EBITDA, and raised FY 2027 revenue guidance. Despite this, shares fell 20% due to high CapEx guidance. The company is seen as undervalued by some analysts.
How this was made
The 30-second read
Why it matters
The earnings beat and aggressive FY 2027 guidance provide fresh data, but the steep valuation multiple and large CapEx plan triggered a sell‑off, creating a mixed short‑term outlook.
Market read
First‑time earnings disclosure with strong growth metrics, yet market reaction is sharply negative, making the story highly relevant for traders.
What to watch
CapEx guidance of $40‑45B may be viewed as a long‑term growth catalyst rather than a short‑term risk.
Background
Nebius (NBIS) is a GPU‑as‑a‑service provider that offers a full‑stack AI platform for cloud compute.
Ticker impact
Nebius reported Q3 earnings beating estimates with 571% YoY revenue growth and issued FY 2027 revenue guidance, causing a 20% share drop.
likely further pressure as investors digest the high valuation multiple despite growth
The earnings surprise and guidance are new, but the market reaction (20% drop) suggests sellers may dominate until valuation concerns ease.
Market effects
Highlights rapid growth in AI‑cloud compute, pressuring peers to justify valuations.
U.S. AI‑focused cloud providers may see heightened scrutiny on multiples.
Signals broader investor appetite for high‑growth AI infrastructure firms.
Counterpoint
The 571% revenue surge and positive EBITDA suggest the stock is undervalued; buying on the dip could capture upside.
Key entities
- companyNebius
GPU‑as‑a‑service provider reporting Q3 results.
